skp2 targeting suppresses tumorigenesis arf-p53-independent cellular senescence 
cellular senescence recently shown important role opposing tumour initiation promotion senescence induced oncogenes loss tumour suppressor genes thought critically depend induction p19arf-p53 pathway skp2 e3-ubiquitin ligase can act proto-oncogene aberrant overexpression frequently observed human cancers show although skp2 inactivation induce cellular senescence aberrant proto-oncogenic signals well inactivation tumour suppressor genes trigger potent tumour-suppressive senescence response mice cells devoid skp2 notably skp2 inactivation oncogenic-stress-driven senescence neither elicit activation p19arf-p53 pathway dna damage instead depend atf4 p27 p21 demonstrate genetic skp2 inactivation evokes cellular senescence even oncogenic conditions p19arf-p53 response impaired whereas skp2-scf complex inhibitor can trigger cellular senescence p53/pten-deficient cells tumour regression preclinical studies findings therefore provide proof-of-principle evidence pharmacological inhibition skp2 may represent general approach cancer prevention therapy 
